FY2025 EPS Estimates for STOK Increased by Cantor Fitzgerald

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Stoke Therapeutics in a note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn $0.03 per share for the year, up from their prior forecast of ($2.40). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million.

A number of other equities research analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Chardan Capital reissued a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Stock Down 6.6 %

Stoke Therapeutics stock opened at $7.74 on Monday. Stoke Therapeutics has a twelve month low of $7.22 and a twelve month high of $17.58. The company has a market capitalization of $418.56 million, a P/E ratio of -3.69 and a beta of 0.99. The stock’s 50 day moving average is $9.44 and its 200 day moving average is $11.30.

Insider Activity

In related news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 in the last 90 days. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS bought a new position in Stoke Therapeutics in the fourth quarter worth approximately $63,000. Teacher Retirement System of Texas bought a new position in Stoke Therapeutics in the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics during the fourth quarter valued at $124,000. Tower Research Capital LLC TRC lifted its position in Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in Stoke Therapeutics during the fourth quarter valued at about $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.